• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Acumen Pharmaceuticals, Inc. - Common Stock (NQ:ABOS)

    2.101 +0.111 (+5.57%)
    Streaming Delayed Price Updated: 12:26 PM EST, Dec 31, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 71,231
    Open 2.000
    Bid (Size) 2.100 (300)
    Ask (Size) 2.120 (400)
    Prev. Close 1.990
    Today's Range 2.000 - 2.128
    52wk Range 0.8551 - 2.460
    Shares Outstanding 40,501,258
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 ALTITUDE-AD Clinical Trial at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +13.6%
    +13.6%
    1 Month
    +10.6%
    +10.6%
    3 Month
    +22.9%
    +22.9%
    6 Month
    +89.3%
    +89.3%
    1 Year
    +20.1%
    +20.1%

    More News

    Read More
    News headline image
    Earnings Scheduled For November 12, 2025 ↗
    Via Benzinga
    News headline image
    Acumen Pharmaceuticals's Earnings: A Preview ↗
    Via Benzinga
    News headline image
    A Preview Of Acumen Pharmaceuticals's Earnings ↗
    Via Benzinga
    News headline image
    Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People with Early Alzheimer’s Disease
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals Inc (NASDAQ:ABOS) Reports Q3 2025 Earnings, Beats EPS Estimates ↗
    Via Chartmill
    Topics Earnings
    News headline image
    Acumen Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Highlights
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Preview: Acumen Pharmaceuticals's Earnings ↗
    Via Benzinga
    News headline image
    Acumen Pharmaceuticals Appoints George Golumbeski, Ph.D., as Chairman of its Board of Directors
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 12, 2025
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Thursday's Intraday Session ↗
    Via Benzinga
    News headline image
    Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals Presents Studies Showing the Utility of a pTau217 Assay in Screening for a Phase 2 Alzheimer’s Disease Trial and Validates Sabirnetug Oligomer-Selectivity, at the Alzheimer’s Association International Conference (AAIC) 2025
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For August 12, 2025 ↗
    Via Benzinga
    News headline image
    Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery™ Therapy for Alzheimer’s Disease
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer’s Association International Conference (AAIC®) 2025
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For May 13, 2025 ↗
    Via Benzinga
    News headline image
    Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Acumen Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, Acumen Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does Acumen Pharmaceuticals, Inc. - Common Stock trade on?
    Acumen Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Acumen Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for Acumen Pharmaceuticals, Inc. - Common Stock is ABOS on the Nasdaq Stock Market
    What is the current price of Acumen Pharmaceuticals, Inc. - Common Stock?
    The current price of Acumen Pharmaceuticals, Inc. - Common Stock is 2.101
    When was Acumen Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of Acumen Pharmaceuticals, Inc. - Common Stock was at 12/31/25 12:26 PM ET
    What is the market capitalization of Acumen Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of Acumen Pharmaceuticals, Inc. - Common Stock is 85.09M
    How many shares of Acumen Pharmaceuticals, Inc. - Common Stock are outstanding?
    Acumen Pharmaceuticals, Inc. - Common Stock has 85M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.